ScaleReady, a cell therapy manufacturing company, and CTMC, a joint venture between National Resilience and the MD Anderson Cancer Center, entered into a collaborative partnership to help lessen the manufacturing barriers holding back cell and gene therapies from reaching more patients by integrating cutting-edge automation tools.

The agreement was designed to enable CTMC to strategically scale the recently completed GMP facility to drive high-throughput manufacturing utilizing the automated, closed system capabilities of the Fresenius Kabi Lovo® and Cue® cell processing systems.

“CTMC uses products with a solid track record of clinical and commercially approved cell therapy successes. ScaleReady’s expertise and platform access will help us to leverage innovative technologies, like the Lovo, for our cell therapy process,” said Laine Linden, head of CTMC technical operations.

“With the addition of the Fresenius Kabi Cue to our manufacturing platform, we hope to drive down variability and increase the number of patients we can successfully treat by automating and closing the final fill and finish steps of our cell therapy products.”

“By providing this facility and [CTMC’s] technical experts with the Cue system, we can functionally close the critical final fill and finish steps, which have historically been manual and open processes,” added Josh Ludwig, global commercial director, ScaleReady. “This technology brings a new level of automation and scalability. Our expanded partnership with CTMC will significantly impact not only the research and the organization but also the patients in need of life-saving therapies.”

Previous articleProtein Guard Mechanism May Be Used against Infectious Disease and Cancer
Next articleAI-Based Drug Discovery Company Atomwise Sets Its Sights on Inflammatory Disease Market